STOCKHOLM, March 28, 2022 /PRNewswire/ -- Moberg Pharma
AB (publ) have submitted its marketing authorization application
for MOB-015 (nail fungus treatment). The company has submitted the
application in Europe through the
decentralized procedure, and market approval is expected in
2023.
Moberg Pharma have submitted a full application, which offers
the possibility of data exclusivity in Europe for up to ten years following market
approval. The Swedish Medical Products Agency is the reference
member state and will lead the review of the application. The
company's goal is to receive its first market approval and launch
MOB-015 in 2023.
"Submitting the Marketing Authorization Application in
Europe is a key milestone in our
journey to launch a new and improved nail fungus drug. MOB-015 is
uniquely positioned through its high antifungal efficacy, since
there is significant need for a treatment that truly cures the nail
infection," says Anna Ljung, CEO
of Moberg Pharma AB.
For additional information, please contact:
Anna Ljung, CEO, telephone:
+46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se
About this information
This information is information that Moberg Pharma AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact persons set out above, at 8.00
a.m. CET on March
28th, 2022.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/moberg-pharma/r/european-marketing-authorization-application-for-mob-015-submitted,c3529030
The following files are available for download:
https://mb.cision.com/Main/1662/3529030/1551387.pdf
|
European marketing
authorization application for MOB-015 submitted
|
View original
content:https://www.prnewswire.com/news-releases/european-marketing-authorization-application-for-mob-015-submitted-301511439.html
SOURCE Moberg Pharma